Setmelanotide: First Approval

被引：121

作者：

Markham, Anthony ^{[1
]}

机构：

[1] Springer Nat, Private Bag 65901, Auckland 0754, New Zealand

来源：

DRUGS | 2021年 / 81卷 / 03期

关键词：

D O I：

10.1007/s40265-021-01470-9

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Setmelanotide (IMCIVREE (TM), Rhythm Pharmaceuticals) is a melanocortin-4 (MC4) receptor agonist developed for the treatment of obesity arising from proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or leptin receptor (LEPR) deficiency. The drug has received its first approval in the USA for chronic weight management in patients 6 years and older with obesity caused by POMC, PCSK1 and LEPR deficiency and has been granted PRIority MEdicines (PRIME) designation by the European Medicines Agency for the treatment of obesity and the control of hunger associated with deficiency disorders of the MC4 receptor pathway. Setmelanotide is also being developed in other rare genetic disorders associated with obesity including Bardet-Biedl Syndrome, Alstrom Syndrome, POMC and other MC4R pathway heterozygous deficiency obesities, and POMC epigenetic disorders. This article summarizes the milestones in the development of setmelanotide leading to this first approval for obesity caused by POMC, PCSK1 and LEPR deficiency.

引用

页码：397 / 403

页数：7

共 16 条

[1] Magel2-null mice are hyper-responsive to setmelanotide, a melanocortin 4 receptor agonist [J].

Bischof, Jocelyn M. ;

Van Der Ploeg, Lex H. T. ;

Colmers, William F. ;

Wevrick, Rachel .

BRITISH JOURNAL OF PHARMACOLOGY, 2016, 173 (17) :2614-2621

[2] RM-493, a Melanocortin-4 Receptor (MC4R) Agonist, Increases Resting Energy Expenditure in Obese Individuals [J].

Chen, Kong Y. ;

Muniyappa, Ranganath ;

Abel, Brent S. ;

Mullins, Katherine P. ;

Staker, Pamela ;

Brychta, Robert J. ;

Zhao, Xiongce ;

Ring, Michael ;

Psota, Tricia L. ;

Cone, Roger D. ;

Panaro, Brandon L. ;

Gottesdiener, Keith M. ;

Van der Ploeg, Lex H. T. ;

Reitman, Marc L. ;

Skarulis, Monica C. .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2015, 100 (04) :1639-1645

[3] Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials [J].

Clement, Karine ;

van den Akker, Erica ;

Argente, Jesus ;

Bahm, Allison ;

Chung, Wendy K. ;

Connors, Hillori ;

De Waele, Kathleen ;

Farooqi, I. Sadaf ;

Gonneau-Lejeune, Julie ;

Gordon, Gregory ;

Kohlsdorf, Katja ;

Poitou, Christine ;

Puder, Lia ;

Swain, James ;

Stewart, Murray ;

Yuan, Guojun ;

Wabitsch, Martin ;

Kuehnen, Peter .

LANCET DIABETES & ENDOCRINOLOGY, 2020, 8 (12) :960-970

[4] MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency [J].

Clement, Karine ;

Biebermann, Heike ;

Farooqi, I. Sadaf ;

Van der Ploeg, Lex ;

Wolters, Barbara ;

Poitou, Christine ;

Puder, Lia ;

Fiedorek, Fred ;

Gottesdiener, Keith ;

Kleinau, Gunnar ;

Heyder, Nicolas ;

Scheerer, Patrick ;

Blume-Peytavi, Ulrike ;

Jahnke, Irina ;

Sharma, Shubh ;

Mokrosinski, Jacek ;

Wiegand, Susanna ;

Mueller, Anne ;

Weiss, Katja ;

Mai, Knut ;

Spranger, Joachim ;

Grueters, Annette ;

Blankenstein, Oliver ;

Krude, Heiko ;

Kuehnen, Peter .

NATURE MEDICINE, 2018, 24 (05) :551-+

[5] Effect of setmelanotide, a melanocortin-4 receptor agonist, on obesity in Bardet-Biedl syndrome [J].

Haws, Robert ;

Brady, Sheila ;

Davis, Elisabeth ;

Fletty, Kristina ;

Yuan, Guojun ;

Gordon, Gregory ;

Stewart, Murray ;

Yanovski, Jack .

DIABETES OBESITY & METABOLISM, 2020, 22 (11) :2133-2140

[6]

Ipsen Limited, 2010, IPS GRANTS RHYTHM EX

[7] Chronic Treatment With a Melanocortin-4 Receptor Agonist Causes Weight Loss, Reduces Insulin Resistance, and Improves Cardiovascular Function in Diet-Induced Obese Rhesus Macaques [J].

Kievit, Paul ;

Halem, Heather ;

Marks, Daniel L. ;

Dong, Jesse Z. ;

Glavas, Maria M. ;

Sinnayah, Puspha ;

Pranger, Lindsay ;

Cowley, Michael A. ;

Grove, Kevin L. ;

Culler, Michael D. .

DIABETES, 2013, 62 (02) :490-497

[8] Proopiomelanocortin Deficiency Treated with a Melanocortin-4 Receptor Agonist [J].

Kuehnen, Peter ;

Clement, Karine ;

Wiegand, Susanna ;

Blankenstein, Oliver ;

Gottesdiener, Keith ;

Martini, Lea L. ;

Mai, Knut ;

Blume-Peytavi, Ulrike ;

Grueters, Annette ;

Krude, Heiko .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (03) :240-246

[9]

Rhythm Pharmaceuticals, 2020, RHYTHM PHARM ANN FDA

[10]

Rhythm Pharmaceuticals, 2016, THYTHM CAM ANN LIC A

← 1 2 →